# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash....
Critical Care has approximately 4,500 employees with most based in Irvine, California. In 2023, the business generated more tha...
With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the aft...
Goldman Sachs analyst David Roman initiates coverage on Becton Dickinson (NYSE:BDX) with a Buy rating and announces Price Ta...
Jim Cramer has highlighted the potential benefits for U.S. automakers, particularly Ford and General Motors, following the Bide...
- Reuters
Barclays analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Overweight and raises the price target from $305 ...
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance...